Flagship fields of research in line
with the region's cutting-edge facilities

INFECTIOLOGY

In this domain, Adebag is using the expertise of Lyonbiopôle and the Infectiology Innovation Foundation (FInovI).

Lyonbiopole a world competitive cluster

• The cluster is focused on infectious diseases with a comprehensive approach ranging from diagnostics and prevention (vaccines) up to treatment, exploring new methods made possible by biotechnology (therapeutic vaccines, monoclonal antibodies, gene and cell therapy and more) to build a healthcare shield in order to meet public health challenges and remain a leader on thriving markets.
• It meets healthcare and economic challenges: the re-emergence of infectious diseases and pathologies induced by viral pathogens (such as virally induced cancers), pandemics, epizootics, the risk of bioterrorism and more.
• It is active in dynamic markets: the vaccine market is growing by 25% every year, and the diagnostics market by 6%.
• It is led by firms with the involvement of all major stakeholders within the cluster’s scope of action

  The main strength of this healthcare shield specialized in infectious diseases is that it incorporates the entire chain of activity, from identification of a virus to protection of the populations at risk. Lyonbiopôle is built upon a particularly advantageous blend of expertise, which comes from its distinctive know-how in complementary fields:

• Firms working on animal health and human health, a vector for combined innovation
• A strong link between diagnostics, vaccines and medical devices that are highly complementary in the approaches to infectious diseases and new therapies
• Scientific expertise in functional and industrial biology in Lyon and structural/micro-nanobiotechnologies in Grenoble

President : Philippe Archinard
Directeur : Yves Laurent
Contact : isabelle.scarabin@lyonbiopole.com
www.lyonbiopole.com

FInovI : Scientific Cooperation Foundation for Innovation in Infectiology

The initial capital of FINOVI consists of a €13 M grant from the state and a €3.5 M grant from the founders. There are 9 founders, made up of the main French research and higher education establishments (CNRS, INSERM, ENS, UCBL, UJF, INRA, INRIA, Institut Pasteur) and the Lyonbiopôle Centre of Excellence.

The goal of the FINOVI foundation is to develop innovative research for new therapeutic and preventative solutions against infectious diseases. The scientific challenges of this project are manifold:

• To develop cutting-edge knowledge on the molecular and physiological mechanisms of infection via pathogenic micro-organisms
• To strengthen links between fundamental research and hospital departments to better tackle public health issues
• To put this knowledge at the disposal of the Lyonbiopole World Centre of Excellence in Infectiology so as to reinforce the development of the French health defence system
• With the combined effort of these two centres, to propel infectiology research in Lyon and Grenoble to a level of international excellence and visibility.

The FINOVI foundation is a group of 27 public research units with over 360 researchers, research teachers and post-docs based in Lyon or Grenoble . To reach these objectives, it has developed a research strategy and policy focused around 4 key avenues:

• The development of innovative research projects
• The development of innovative projects
• The added value dimension
• International recognition and appeal

The resources which will be made available for this strategy on the Lyon and Grenoble sites aim to:

• attract top-level researchers
• create new teams on a contractual basis
• launch innovative multidisciplinary research projects
• support shared technological infrastructures and their related services,
• become a key influential centre of knowledge

Contact : christelle.bidaud@finovi.org